Internal medicine

Adverse effect

Clinical endpoint

Vancomycin

Pharmacist

Population

Antibiotics

Family medicine

Bacteria

Biology

Microbiology

Pharmacy

Intensive care medicine

Randomized controlled trial

Pneumonia

Meropenem

Staphylococcus aureus

Linezolid

Genetics

Medicine

Antibiotic resistance

Environmental health

The Lancet Infectious Diseases

Cefiderocol was non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. The results suggest that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial